等待開盤 09-10 09:30:00 美东时间
-0.005
-0.01%
Achieves tenfold bandwidth increase, streamlined deployment, and increased network visibility PLANO, Texas, Aug. 18, 2025 /PRNewswire/ -- Ribbon Communications Inc. (Nasdaq: RBBN), a global ...
08-18 20:00
在全球能源转型和可持续发展的大背景下,建筑作为碳排放的重要载体,其绿色转型已不仅是技术命题,更关乎人类对 “栖居” 本质的重新审视。在 “双碳” 目标与建筑美学...
08-11 17:32
Alterity Therapeutics Limited (‘ATH'): ASX Aware LetterASX refers to the following:A.ATH's announcement titled ‘Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study'
08-04 19:59
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an
07-24 19:28
– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints –– MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring –– bioMUSE Study shows higher α- synuclein concentration
05-12 19:39
4月14日,国内领先体育运动品牌361度(01361.HK)公布了2025年第一季度运营成果,数据显示,公司主品牌零售额同比增长10%–15%,童装业务零售额同...
04-15 09:07
Collins Aerospace, an RTX business (NYSE:RTX), has secured a six-year renewal pact with Heathrow Airline Operators' Committee (AOC) to continue providing its ARINC cMUSE solution across all four Londo...
04-09 15:28
Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis.
04-03 03:12
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Wednesday that a Phase 3 trial for a high-dose version of its multiple sclerosis therapy Ocrevus (ocrelizumab) failed in a Phase 3 trial, sending the shares...
04-03 00:15
文 | 冯睿洋 编辑 | 刘士武 AI在游戏行业的落地可谓神速,大小厂商们纷纷将AI与游戏进行了融合。 腾讯游戏让《和平精英》的虚拟人物「吉利」化身AI驱动...
03-17 17:08